(NASDAQ: EVGN) Evogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 103.77%.
Evogene's earnings in 2025 is -$2,749,000.On average, 3 Wall Street analysts forecast EVGN's earnings for 2025 to be -$5,512,258, with the lowest EVGN earnings forecast at -$5,296,091, and the highest EVGN earnings forecast at -$5,674,383. On average, 3 Wall Street analysts forecast EVGN's earnings for 2026 to be -$12,002,497, with the lowest EVGN earnings forecast at -$11,531,810, and the highest EVGN earnings forecast at -$12,355,511.
In 2027, EVGN is forecast to generate -$7,557,127 in earnings, with the lowest earnings forecast at -$7,260,770 and the highest earnings forecast at -$7,779,396.